Zoetis Inc

ZTS

Equity

ISIN US98978V1035 / Valor 19276994

New York Stock Exchange, Inc (2024-11-21)

USD 176.71+0.59%

Zoetis Inc
UMushroom community rating:

5.00 2 votes No rating yet

NegativeNeutralPositive

About company

Zoetis Inc. is a global leader in the animal health industry, providing a comprehensive range of products and services that cater to the health needs of animals. With operations spanning over 100 countries, the company's portfolio encompasses a wide array of medicines, vaccines, diagnostics, and technologies designed to support the health and well-being of animals across various sectors, including livestock and companion animals. Zoetis is recognized for its innovative approach in developing solutions that address both common and emerging health challenges faced by animals, thereby contributing significantly to the global animal health sector. The company's commitment to research and development is evident in its robust pipeline, which ensures a continuous introduction of new and improved products to the market, further solidifying its position as a key player in the animal health industry.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

Zoetis Inc. reported revenue of $2.4 billion for the second quarter of 2024, marking an 8% increase compared to the second quarter of 2023. On an operational basis, revenue grew by 11% year-over-year. This growth was driven by strong demand for the company's innovative products across both companion animal and livestock portfolios.

Net Income

For the second quarter of 2024, Zoetis Inc. reported a net income of $624 million, or $1.37 per diluted share. This represents a decrease of 7% in net income and a 6% decrease in diluted earnings per share compared to the same period in 2023. The decline was attributed to various factors, including purchase accounting adjustments and acquisition-related costs.

Adjusted Net Income

Zoetis Inc.'s adjusted net income for the second quarter of 2024 was $711 million, or $1.56 per diluted share. This reflects an increase of 9% in adjusted net income and an 11% increase in adjusted diluted earnings per share on a reported basis. On an operational basis, adjusted net income grew by 18%, and adjusted diluted earnings per share increased by 20%.

Segment Performance

In the second quarter of 2024, Zoetis Inc.'s U.S. segment reported revenue of $1.3 billion, a 12% increase compared to the same quarter in 2023. The International segment reported revenue of $1.0 billion, reflecting a 4% increase on a reported basis and a 10% increase operationally. Growth in both segments was driven by strong sales of companion animal and livestock products.

Full-Year Guidance

Zoetis Inc. has raised its full-year 2024 revenue guidance to a range of $9.100 billion to $9.250 billion, reflecting operational growth of 9% to 11%. The company also updated its full-year adjusted net income guidance to a range of $2.640 billion to $2.690 billion, representing operational growth of 13.5% to 15.5%. Adjusted diluted EPS is now expected to be between $5.78 and $5.88.

Summarized from source with an LLMView Source

Key figures

-1.13%1Y

-22.0%3Y

47.0%5Y

Performance

25.0%1Y

27.6%3Y

29.0%5Y

Volatility